Taken together, our results indicated that by increasing DEPTOR levels, Ube2c deletion inactivated mTORC signaling to inhibit KrasG12D-induced lung tumorigenesis, and suggested that UBE2C could be an effective therapeutic target for management of lung cancer associated with Kras mutation. This evidence concerns the gene UBE2C and lung carcinoma.